Literature DB >> 33797920

Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma.

Joana Pinto1, Filipa Amaro1, Ana Rita Lima1, Carina Carvalho-Maia2,3, Carmen Jerónimo2,3,4, Rui Henrique2,3,4, Maria de Lourdes Bastos1, Márcia Carvalho1,5, Paula Guedes de Pinho1.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer usually associated with asymptomatic development and risk of systemic progression. Hence, reliable molecular biomarkers of ccRCC are needed to provide early and minimally invasive detection. In this study, urinary volatilome profiling of patients diagnosed with ccRCC (n = 75), and cancer-free controls (n = 75), was performed to investigate the presence of a volatile signature characteristic of ccRCC. Volatile organic compounds (VOCs) in general, and more specifically volatile carbonyl compounds (VCCs), present in urine were extracted by headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (HS-SPME-GC-MS). Supervised multivariate models showed a good discriminatory power of ccRCC patients from controls in urine. Overall, 22 volatile metabolites were found significantly altered between the two groups, including aldehydes, ketones, aromatic hydrocarbons, and terpenoids. A candidate six-biomarker panel, comprising octanal, 3-methylbutanal, benzaldehyde, 2-furaldehyde, 4-heptanone, and p-cresol, depicted the best performance for ccRCC detection with 83% sensitivity, 79% specificity, and 81% accuracy. Moreover, the ccRCC urinary volatilome signature suggested dysregulation of energy metabolism and overexpression of enzymes associated with carcinogenesis. These findings provide the molecular basis for the fine-tuning of gas-sensing materials for application in the development of a bioelectronic sensor.

Entities:  

Keywords:  clear cell renal cell carcinoma; diagnostic biomarkers; gas chromatography-mass spectrometry; urine; volatilome

Year:  2021        PMID: 33797920     DOI: 10.1021/acs.jproteome.0c00936

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  2 in total

1.  Solid-phase microextraction: a fit-for-purpose technique in biomedical analysis.

Authors:  Barbara Bojko
Journal:  Anal Bioanal Chem       Date:  2022-05-24       Impact factor: 4.478

2.  The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.

Authors:  Nana Dong; Shengmin Zhang; Shuangjun Zhang; Qiongqiong Zhao; Donghua Zhang; Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-14       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.